Age-related macular degeneration: genetic and environmental factors of disease.

Age-related macular degeneration (AMD) is the most common cause of visual impairment among the elderly in developed countries, and its prevalence is thus increasing as the population ages; however, treatment options remain limited because the etiology and pathogenesis of AMD are incompletely defined. Recently, much progress has been made in gene discovery and mechanistic studies, which clearly indicate that AMD involves the interaction of multiple genetic and environmental factors. The identification of genes that have a substantial impact on the risk for AMD is not only facilitating the diagnosis and screening of populations at risk but is also elucidating key molecular pathways of pathogenesis. Pharmacogenetic studies of treatment responsiveness among patients with the "wet" form of AMD are increasingly proving to be clinically relevant; pharmacogenetic approaches hold great promise for both identifying patients with the best chance for vision recovery as well as tailoring individualized therapies.

[1]  Giovanni Sato,et al.  Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor. , 2010, Ophthalmology.

[2]  Aaron Y. Lee,et al.  Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC) , 2010, Proceedings of the National Academy of Sciences.

[3]  Margaret A. Pericak-Vance,et al.  Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration , 2010, Proceedings of the National Academy of Sciences.

[4]  M. Sporn,et al.  Cigarette smoking, oxidative stress, the anti-oxidant response through Nrf2 signaling, and Age-related Macular Degeneration , 2010, Vision Research.

[5]  S. Chakrabarti,et al.  The molecular genetic basis of age-related macular degeneration: an overview , 2009, Journal of Genetics.

[6]  Aaron Y. Lee,et al.  Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration , 2009, Molecular vision.

[7]  B. Rosner,et al.  Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. , 2009, Investigative ophthalmology & visual science.

[8]  P. Mitchell,et al.  Toll-like receptor polymorphisms and age-related macular degeneration: replication in three case-control samples. , 2009, Investigative ophthalmology & visual science.

[9]  I. Constable,et al.  Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. , 2009, Ophthalmology.

[10]  Bin Wang,et al.  HTRA1 promoter polymorphism and risk of age-related macular degeneration: a meta-analysis. , 2009, Annals of epidemiology.

[11]  Anand Swaroop,et al.  Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. , 2009, Annual review of genomics and human genetics.

[12]  Johanna M Seddon,et al.  Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. , 2009, Investigative ophthalmology & visual science.

[13]  M. Brantley,et al.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy , 2009, Eye.

[14]  Chi-Chao Chan,et al.  Molecular pathology of age-related macular degeneration , 2009, Progress in Retinal and Eye Research.

[15]  M. Brantley,et al.  Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab , 2008, British Journal of Ophthalmology.

[16]  I. Chowers,et al.  Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel , 2008, Molecular vision.

[17]  M. Xiong,et al.  Multifactor Effects and Evidence of Potential Interaction between Complement Factor H Y402H and LOC387715 A69S in Age-Related Macular Degeneration , 2008, PloS one.

[18]  J. Ott,et al.  Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss , 2008, Journal of Medical Genetics.

[19]  A. Hofman,et al.  Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. , 2008, Ophthalmology.

[20]  G. Parmigiani,et al.  Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. , 2008, The New England journal of medicine.

[21]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[22]  Martin Oppermann,et al.  Systemic Complement Activation in Age-Related Macular Degeneration , 2008, PloS one.

[23]  F. Parmeggiani,et al.  Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.

[24]  J. Ott,et al.  CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. , 2008, Ophthalmology.

[25]  A. Luff,et al.  An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment , 2008, Eye.

[26]  Katherine M. James,et al.  Toll-like receptor polymorphisms and age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.

[27]  J. Haines,et al.  Deletion of CFHR3 and CFHR1 genes in age-related macular degeneration. , 2008, Human molecular genetics.

[28]  Sharon D. Solomon,et al.  Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) Project. , 2008, Archives of ophthalmology.

[29]  F. Parmeggiani,et al.  Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration , 2007, Pharmacogenetics and genomics.

[30]  M. Brantley,et al.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. , 2007, Ophthalmology.

[31]  P. Tommila,et al.  The Effect of Complement Factor H Y402H Polymorphism on the Outcome of Photodynamic Therapy in Age-related Macular Degeneration , 2007, European journal of ophthalmology.

[32]  P. Debré,et al.  CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. , 2007, The Journal of clinical investigation.

[33]  Johanna M Seddon,et al.  Variation in complement factor 3 is associated with risk of age-related macular degeneration , 2007, Nature Genetics.

[34]  I. Deary,et al.  Complement C3 variant and the risk of age-related macular degeneration. , 2007, The New England journal of medicine.

[35]  G. Abecasis,et al.  Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. , 2007, Human molecular genetics.

[36]  P. Mitchell,et al.  The LOC387715 polymorphism and age-related macular degeneration: replication in three case-control samples. , 2007, Investigative ophthalmology & visual science.

[37]  Chi Pui Pang,et al.  HTRA1 promoter polymorphism in wet age-related macular degeneration. , 2007, Science.

[38]  L. Sobrin,et al.  Review of Genetics in Age Related Macular Degeneration , 2007, Seminars in ophthalmology.

[39]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[40]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[41]  N. Camp,et al.  A Variant of the HTRA1 Gene Increases Susceptibility to Age-Related Macular Degeneration , 2006, Science.

[42]  J. Attia,et al.  Association between apolipoprotein E polymorphisms and age-related macular degeneration: A HuGE review and meta-analysis. , 2006, American journal of epidemiology.

[43]  Jeremy Nathans,et al.  Macular degeneration: recent advances and therapeutic opportunities , 2006, Nature Reviews Neuroscience.

[44]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[45]  J. Escardo,et al.  VEGF polymorphisms are associated with neovascular age-related macular degeneration. , 2006, Human molecular genetics.

[46]  Yun Li,et al.  CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration , 2006, Nature Genetics.

[47]  Johanna M Seddon,et al.  Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration , 2006, Nature Genetics.

[48]  Johanna M Seddon,et al.  The genetics of age-related macular degeneration: a review of progress to date. , 2006, Survey of ophthalmology.

[49]  Baitang Ning,et al.  Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Haines,et al.  Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. , 2006, American journal of human genetics.

[51]  Tim Clausen,et al.  The Role of Human HtrA1 in Arthritic Disease* , 2006, Journal of Biological Chemistry.

[52]  R. T. Smith,et al.  Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration , 2006, Nature Genetics.

[53]  R. Avery,et al.  Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. , 2006, Ophthalmology.

[54]  R. Klein,et al.  Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. , 2006, Ophthalmology.

[55]  Don H. Anderson,et al.  Age‐related macular degeneration—emerging pathogenetic and therapeutic concepts , 2006, Annals of medicine.

[56]  G. Abecasis,et al.  Meta-analysis of genome scans of age-related macular degeneration. , 2005, Human molecular genetics.

[57]  W R Green,et al.  Senile macular degeneration: a histopathologic study. , 1977, Transactions of the American Ophthalmological Society.

[58]  G. Abecasis,et al.  Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration. , 2005, Human molecular genetics.

[59]  R. T. Smith,et al.  A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[60]  A. Edwards,et al.  Complement Factor H Polymorphism and Age-Related Macular Degeneration , 2005, Science.

[61]  J. Gilbert,et al.  Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration , 2005, Science.

[62]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[63]  V. Sheffield,et al.  Missense variations in the fibulin 5 gene and age-related macular degeneration. , 2004, The New England journal of medicine.

[64]  M. Smith-Wheelock,et al.  Association of apolipoprotein E alleles with susceptibility to age-related macular degeneration in a large cohort from a single center. , 2004, Investigative ophthalmology & visual science.

[65]  Robyn H Guymer,et al.  The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. , 2004, Investigative ophthalmology & visual science.

[66]  M. Kawaichi,et al.  HtrA1 serine protease inhibits signaling mediated by Tgfβ family proteins , 2004, Development.

[67]  Johanna M Seddon,et al.  Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. , 2003, Ophthalmology.

[68]  Donna Arnett,et al.  Twin study of age-related macular degeneration , 2003, Ophthalmic epidemiology.

[69]  Masaru Miyagi,et al.  Drusen proteome analysis: An approach to the etiology of age-related macular degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[70]  M. Lavail,et al.  Low docosahexaenoic acid levels in rod outer segments of rats with P23H and S334ter rhodopsin mutations. , 2002, Molecular vision.

[71]  Harold Snieder,et al.  Genetic influence on early age-related maculopathy: a twin study. , 2002, Ophthalmology.

[72]  Joan W. Miller,et al.  Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. , 2002, Archives of ophthalmology.

[73]  J. Haines,et al.  A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy , 2002, Ophthalmic genetics.

[74]  L. V. Johnson,et al.  Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. , 2001, Experimental eye research.

[75]  C. Curcio,et al.  Murine high-fat diet and laser photochemical model of basal deposits in Bruch membrane. , 2001, Archives of ophthalmology.

[76]  Robert F. Mullins,et al.  An Integrated Hypothesis That Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch's Membrane Interface in Aging and Age-Related Macular Degeneration , 2001, Progress in Retinal and Eye Research.

[77]  R. Klein,et al.  Risk of incident age-related eye diseases in people with an affected sibling : The Beaver Dam Eye Study. , 2001, American journal of epidemiology.

[78]  W. Willett,et al.  Dietary fat and risk for advanced age-related macular degeneration. , 2001, Archives of ophthalmology.

[79]  G. Hageman,et al.  Structure and composition of drusen associated with glomerulonephritis: Implications for the role of complement activation in drusen biogenesis , 2001, Eye.

[80]  A Hofman,et al.  Risk factors for age-related macular degeneration: Pooled findings from three continents. , 2001, Ophthalmology.

[81]  R. Allikmets,et al.  Further evidence for an association of ABCR alleles with age-related macular degeneration. The International ABCR Screening Consortium. , 2000, American journal of human genetics.

[82]  S. Meri,et al.  Molecular Mechanisms of Target Recognition in an Innate Immune System: Interactions Among Factor H, C3b, and Target in the Alternative Pathway of Human Complement1 2 , 2000, The Journal of Immunology.

[83]  S. Russell,et al.  Drusen associated with aging and age‐related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[84]  S. Ranganathan,et al.  Pinpointing the putative heparin/sialic acid-binding residues in the 'sushi' domain 7 of factor H: a molecular modeling study. , 1999, Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.

[85]  G. Hageman,et al.  Molecular composition of drusen as related to substructural phenotype. , 1999, Molecular vision.

[86]  H. Kaplan,et al.  Fas ligand (CD95 ligand) controls angiogenesis beneath the retina , 1999, Nature Medicine.

[87]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[88]  A Hofman,et al.  Genetic risk of age-related maculopathy. Population-based familial aggregation study. , 1998, Archives of ophthalmology.

[89]  P. Mitchell,et al.  Family history and age-related maculopathy: the Blue Mountains Eye Study. , 1998, Australian and New Zealand journal of ophthalmology.

[90]  A. Hofman,et al.  Genetic association of apolipoprotein E with age-related macular degeneration. , 1998, American journal of human genetics.

[91]  R. Klein,et al.  Relation of smoking to the incidence of age-related maculopathy. The Beaver Dam Eye Study. , 1998, American journal of epidemiology.

[92]  P. Campochiaro,et al.  Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. , 1997, The American journal of pathology.

[93]  J M Seddon,et al.  Familial aggregation of age-related maculopathy. , 1997, American journal of ophthalmology.

[94]  S. Seregard,et al.  Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. , 1996, Investigative ophthalmology & visual science.

[95]  H. Luukinen,et al.  Risk factors of age-related maculopathy in a population 70 years of age or older. , 1996, Ophthalmology.

[96]  Johannes R. Vingerling,et al.  The prevalence of age-related maculopathy in the Rotterdam Study. , 1995, Ophthalmology.

[97]  M. Klein,et al.  Heredity and age-related macular degeneration. Observations in monozygotic twins. , 1994, Archives of ophthalmology.

[98]  R. Klein,et al.  Prevalence of age-related maculopathy. The Beaver Dam Eye Study. , 1992, Ophthalmology.

[99]  F L Ferris,et al.  Senile macular degeneration: a case-control study. , 1983, American journal of epidemiology.

[100]  P. Tommila,et al.  Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. , 2010, Ophthalmology.

[101]  M. Cahill,et al.  The pathophysiology of cigarette smoking and age-related macular degeneration. , 2010, Advances in experimental medicine and biology.

[102]  F. Parmeggiani,et al.  Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. , 2009, Pharmacogenomics.

[103]  E. Rimm,et al.  A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. , 2007, Archives of ophthalmology.

[104]  J. Hoh,et al.  Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. , 2006, Human molecular genetics.

[105]  P. Penfold,et al.  Senile macular degeneration: The involvement of immunocompetent cells , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[106]  G. Abecasis,et al.  Strong Association of the Y 402 H Variant in Complement Factor H at 1 q 32 with Susceptibility to Age-Related Macular Degeneration , 2005 .

[107]  D. Weeks,et al.  Susceptibility genes for age-related maculopathy on chromosome 10q26. , 2005, American journal of human genetics.

[108]  Lars G Fritsche,et al.  Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. , 2005, Human molecular genetics.

[109]  Benita J. O’Colmain,et al.  Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.

[110]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[111]  A. Munnich,et al.  The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. , 1998, American journal of ophthalmology.

[112]  R. Klein,et al.  Sibling correlations and segregation analysis of age‐related maculopathy: The beaver dam eye study , 1994, Genetic epidemiology.

[113]  A. Dosso,et al.  Monozygotic twin brothers with age-related macular degeneration. , 1992, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.